These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34897154)

  • 1. Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.
    Hatanaka T; Kakizaki S; Kaburagi T; Saito N; Nakano S; Hazama Y; Yoshida S; Hachisu Y; Tanaka Y; Yoshinaga T; Kashiwabara K; Naganuma A; Yamazaki Y; Uraoka T; Nagashima S; Takahashi M; Nishizawa T; Murata K; Okamoto H
    Intern Med; 2022 May; 61(10):1537-1543. PubMed ID: 34897154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
    Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.
    Shah R; Barclay ST; Peters ES; Fox R; Gunson R; Bradley-Stewart A; Shepherd SJ; MacLean A; Tong L; van Vliet VJE; Ngan Chiu Bong M; Filipe A; Thomson EC; Davis C
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues.
    Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
    J Infect; 2022 Oct; 85(4):e94-e95. PubMed ID: 35810942
    [No Abstract]   [Full Text] [Related]  

  • 7. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
    Krishnan P; Pilot-Matias T; Schnell G; Tripathi R; Ng TI; Reisch T; Beyer J; Dekhtyar T; Irvin M; Xie W; Larsen L; Mensa FJ; Collins C
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
    J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
    Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
    Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
    PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glecaprevir/Pibrentasvir: First Global Approval.
    Lamb YN
    Drugs; 2017 Oct; 77(16):1797-1804. PubMed ID: 28929412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
    Sánchez Suárez MM; Martín Roldán A; Cantudo Cuenca MR
    Rev Esp Quimioter; 2024 Jun; 37(3):283-284. PubMed ID: 38638059
    [No Abstract]   [Full Text] [Related]  

  • 14. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
    Hubbard H; Lawitz E
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
    Forns X; Feld JJ; Dylla DE; Pol S; Chayama K; Hou J; Heo J; Lampertico P; Brown A; Bondin M; Tatsch F; Burroughs M; Marcinak J; Zhang Z; Emmett A; Gordon SC; Jacobson IM
    Adv Ther; 2021 Jun; 38(6):3409-3426. PubMed ID: 34021887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis.
    Zhang Y; Jiang X; Zhao Y; Xu Y
    J Viral Hepat; 2021 Jan; 28(1):177-185. PubMed ID: 32961624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report.
    Kaba A; Yamanaga S; Hidaka Y; Toyoda M; Kashima M; Takekuma Y; Inadome A; Yokomizo H; Miyata A
    Transplant Proc; 2022 Mar; 54(2):549-551. PubMed ID: 35120765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of Japanese hemophilia patient co-infected with HIV and HCV genotype 4a by glecaprevir/pibrentasvir therapy.
    Sato K; Kanayama Y; Yamazaki Y; Tojima H; Suga T; Uehara D; Kakizaki S; Yanagisawa K; Uraoka T; Ohnishi H; Okamoto H
    Clin J Gastroenterol; 2021 Dec; 14(6):1725-1732. PubMed ID: 34664197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
    Ruwayni AA; AlObary EE; Alyahya KM
    Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.